ω-Agatoxin IVA TFA: Precision Cav2.1 Calcium Channel Blocker for Neuroprotection

Executive Summary: ω-Agatoxin IVA TFA is a peptide toxin from the funnel-web spider, formulated by APExBIO as a trifluoroacetate salt (C8722) for research use (product page). It specifically inhibits P/Q-type (Cav2.1) voltage-gated calcium channels at nanomolar concentrations, with minimal off-target effects on N-type, L-type, or T-type channels. In vitro, it robustly suppresses calcium-dependent neurotransmitter release, including glutamate and GABA, and in vivo, it demonstrates neuroprotection and anticonvulsant efficacy in epilepsy animal models (Asakura et al., 2000). The compound is validated for neuronal calcium current recording and synaptic transmission studies, with typical working concentrations from 100 nM to 1 μM in vitro and 0.01–1 nM in animal models. Reliable storage requires -20°C under nitrogen, protected from moisture and light; solutions should be used promptly after preparation.

Biological Rationale

Voltage-gated calcium channels (VGCCs) mediate presynaptic calcium influx, triggering neurotransmitter release and synaptic transmission. Among VGCCs, P/Q-type (Cav2.1) channels are critically involved in synaptic exocytosis of excitatory amino acids, such as glutamate, in mammalian neurons (Asakura et al., 2000). Dysregulation of Cav2.1 channel activity is implicated in various neuropathologies, including epilepsy, cerebral ischemia, and excitotoxic neuronal injury (related article). Targeted blockade of Cav2.1 channels provides a granular tool to dissect presynaptic mechanisms and protect against pathological glutamate release in brain injury models.

Mechanism of Action of ω-Agatoxin IVA TFA

ω-Agatoxin IVA TFA is a 48-amino-acid peptide isolated from Agelenopsis aperta venom and supplied as a trifluoroacetate salt (molecular weight 5316.27) by APExBIO (product page). It binds selectively to extracellular sites on P/Q-type (Cav2.1) channels, inhibiting calcium influx at nanomolar concentrations (IC₅₀: 1–2 nM for P-type, up to 270.5 nM for Q-type variants with NP motif). This inhibition is highly subtype-specific: N-type (Cav2.2) channels exhibit only weak partial inhibition at 1 μM, while L-type and T-type channels are unaffected at tested concentrations (see in-depth selectivity analysis).

Functionally, ω-Agatoxin IVA TFA reduces calcium-dependent synaptic vesicle exocytosis. This leads to suppression of evoked glutamate and GABA release in neuronal preparations, and attenuates excitatory transmission implicated in epileptogenesis and ischemic injury. In cardiac vagal neurons, it also disrupts nicotinic receptor-mediated activation, supporting studies of autonomic regulation.

Evidence & Benchmarks

• ω-Agatoxin IVA TFA blocks P/Q-type (Cav2.1) calcium channels with an IC₅₀ of 1–2 nM (for P-type channels lacking NP motif) and up to 270.5 nM (for Q-type variants with NP motif) under physiological ionic conditions (APExBIO datasheet).
• It does not block L-type or T-type calcium channels, and only weakly inhibits N-type channels at 1 μM, confirming high subtype selectivity (Asakura et al., 2000).
• In vitro, ω-Agatoxin IVA TFA (100 nM–1 μM) abolishes synaptosomal calcium uptake and evoked glutamate release in rodent brain slices (Asakura et al., 2000).
• Acute epilepsy models in rodents demonstrate anticonvulsant effects at 0.01–1 nM (intracerebroventricular), with significant prolongation of seizure latency and attenuation of kindling progression (experimental workflow guide).
• Neuroprotective effects include reduced cleaved caspase-3 (apoptosis marker) and increased BDNF expression in brain tissue after ischemic insult (Asakura et al., 2000).
• ω-Agatoxin IVA TFA does not impair motor coordination at neuroprotective doses, as assessed by behavioral testing (APExBIO).
• Storage at -20°C under nitrogen is critical. Working solutions must be used promptly; long-term solution storage is not recommended (product guidelines).

Applications, Limits & Misconceptions

ω-Agatoxin IVA TFA is integral to advanced neurophysiology and pharmacology workflows:

• Neuronal calcium current recording (patch-clamp, voltage-clamp) for Cav2.1-specific currents.
• Synaptic transmission mapping to dissect P/Q-type channel contributions.
• Epilepsy and cerebral ischemia animal models for testing neuroprotection, seizure modulation, and apoptosis inhibition.
• Cardiac neuroscience for studying nicotinic regulation of vagal neurons.

This article extends previous summaries such as this mechanism-focused review, by providing validated dosing benchmarks and clarifying boundaries of channel selectivity. For deeper methodological detail, see the workflow optimization guide, which this article further updates with recent in vivo efficacy data.

Common Pitfalls or Misconceptions

• ω-Agatoxin IVA TFA does not inhibit L-type or T-type calcium channels at any tested concentration.
• It provides only partial and weak inhibition of N-type (Cav2.2) channels, even at 1 μM.
• The compound does not reverse established neuronal damage; its primary effect is prevention via channel blockade.
• Long-term storage of prepared solutions is discouraged due to peptide instability; always prepare fresh solutions.
• Use in non-mammalian or non-neuronal systems should be validated for channel homology, as selectivity may differ.

Workflow Integration & Parameters

For in vitro electrophysiology or synaptic assays, ω-Agatoxin IVA TFA is typically applied at 100 nM–1 μM in standard extracellular saline (pH 7.3–7.4, 22–25°C). For brain slice or neuronal culture studies, pre-incubation for 10–30 minutes ensures maximal channel occupancy (application note). In animal models, effective doses are 0.01–1 nM (intracerebroventricular) for acute seizure/ischemia models and 0.1–0.5 nM (intraperitoneal) for epilepsy kindling paradigms. Behavioral and biochemical endpoints include seizure latency, progression, cleaved caspase-3, and BDNF levels.

Storage and handling: Store lyophilized powder at -20°C under nitrogen, shielded from moisture and light. Prepare aqueous solutions immediately before use, and discard any unused aliquots.

Conclusion & Outlook

ω-Agatoxin IVA TFA, as formulated by APExBIO (C8722), remains the reference P/Q-type (Cav2.1) calcium channel blocker for mechanistic neuroscience and translational research. Its high selectivity and robust in vivo efficacy enable precise interrogation of excitatory neurotransmission and neuroprotection. Future directions include expanded use in disease modeling and further structure-activity relationship studies to refine channel subtype targeting. For full product specifications and ordering, visit the APExBIO product page.